These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 15217497)

  • 1. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
    Emberley ED; Alowami S; Snell L; Murphy LC; Watson PH
    Breast Cancer Res; 2004; 6(4):R308-15. PubMed ID: 15217497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.
    Esteva FJ; Sahin AA; Rassidakis GZ; Yuan LX; Smith TL; Yang Y; Gilcrease MZ; Cristofanilli M; Nahta R; Pusztai L; Claret FX
    Clin Cancer Res; 2003 Nov; 9(15):5652-9. PubMed ID: 14654548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
    Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
    Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cluster analysis of S100 gene expression and genes correlating to psoriasin (S100A7) expression at different stages of breast cancer development.
    Carlsson H; Petersson S; Enerbäck C
    Int J Oncol; 2005 Dec; 27(6):1473-81. PubMed ID: 16273201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
    Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
    Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psoriasin interacts with Jab1 and influences breast cancer progression.
    Emberley ED; Niu Y; Leygue E; Tomes L; Gietz RD; Murphy LC; Watson PH
    Cancer Res; 2003 Apr; 63(8):1954-61. PubMed ID: 12702588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psoriasin (S100A7) expression is associated with poor outcome in estrogen receptor-negative invasive breast cancer.
    Emberley ED; Niu Y; Njue C; Kliewer EV; Murphy LC; Watson PH
    Clin Cancer Res; 2003 Jul; 9(7):2627-31. PubMed ID: 12855640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1).
    Kouvaraki MA; Rassidakis GZ; Tian L; Kumar R; Kittas C; Claret FX
    Cancer Res; 2003 Jun; 63(11):2977-81. PubMed ID: 12782606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concordant loss of fragile gene expression early in breast cancer development.
    Guler G; Uner A; Guler N; Han SY; Iliopoulos D; McCue P; Huebner K
    Pathol Int; 2005 Aug; 55(8):471-8. PubMed ID: 15998374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
    Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
    Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
    Naidu R; Wahab NA; Yadav MM; Kutty MK
    Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer.
    Tan EY; Campo L; Han C; Turley H; Pezzella F; Gatter KC; Harris AL; Fox SB
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):467-74. PubMed ID: 17255267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E2F-1: a proliferative marker of breast neoplasia.
    Zhang SY; Liu SC; Al-Saleem LF; Holloran D; Babb J; Guo X; Klein-Szanto AJ
    Cancer Epidemiol Biomarkers Prev; 2000 Apr; 9(4):395-401. PubMed ID: 10794484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A putative role for psoriasin in breast tumor progression.
    Krop I; März A; Carlsson H; Li X; Bloushtain-Qimron N; Hu M; Gelman R; Sabel MS; Schnitt S; Ramaswamy S; Kleer CG; Enerbäck C; Polyak K
    Cancer Res; 2005 Dec; 65(24):11326-34. PubMed ID: 16357139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the cell death genes BNip3 and NIX in ductal carcinoma in situ of the breast; correlation of BNip3 levels with necrosis and grade.
    Sowter HM; Ferguson M; Pym C; Watson P; Fox SB; Han C; Harris AL
    J Pathol; 2003 Dec; 201(4):573-80. PubMed ID: 14648660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome.
    Vestey SB; Perks CM; Sen C; Calder CJ; Holly JM; Winters ZE
    Breast Cancer Res; 2005; 7(1):R119-29. PubMed ID: 15642160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The S100A7-c-Jun activation domain binding protein 1 pathway enhances prosurvival pathways in breast cancer.
    Emberley ED; Niu Y; Curtis L; Troup S; Mandal SK; Myers JN; Gibson SB; Murphy LC; Watson PH
    Cancer Res; 2005 Jul; 65(13):5696-702. PubMed ID: 15994944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.